Correspondence on: ‘Dupilumab as a novel steroid-sparing treatment for IgG₄-related disease’ by Simpson et al

We read with interest the letter by Simpson et al reporting the use of dupilumab in a patient with IgG4-related disease (IgG4-RD).1 Indeed blocking the IL-4/IL-13 pathway is tempting, considering the roles of these cytokines and the physiopathological changes observed during IgG4-RD.2 3 We have also treated with dupilumab a 51-year-old man with IgG4-related dacryoadenitis and sialadenitis (bilateral lacrimal, parotid, sublingual and...